Novartis' Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2─ early breast cancer
Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor …